AUTHORS
Guillaume Lefèvre, MD, PhD, Séverine Bleuse2, Matthieu Groh, MD, MSc3, Antoine Dossier4, Noémie Abisror5, Irène Machelart6, Jeremie Dion7, Guillaume Moulis, MD, PhD8, Nicolas Limal9, Nabil Belfeki10, Bernard Bonnotte, MD, PhD11, Yasmine El Maamar12, Martin Killian13, Emmanuel Ledoult14, Noémie Le Gouellec15, Francois Lifermann16, Maxime Lugosi17, Sarah Melboucy18, Chafika Morati Hafsaoui19, Antoine Néel, MD, PhD20, Mathieu Puyade21, Julien Rohmer, MD22, Nicolas Schleinitz23, Bohrane Slama24, Louis Terriou, MD25, Ludovic Tréfond26, Cécile Lecocq27, Japhete Elenga-Koanga28, Laurine Cadart29, Sarah Khelil30, Kewin Panel31, Florence Roufosse32, Jean-Emmanuel Kahn, MD33
AFFILIATIONS
1 CHU Lille, Reference Center for Hypereosinophilic Syndromes (CEREO), Lille, France
2 CHU Lille, Reference Center for Hypereosinophilic Syndromes (CEREO), Lille, France
3 Foch Hospital, Reference center for Hypereosinophilic Syndromes (CEREO), Suresnes, France
4 Hôpital Bichat, Université Paris Cité, APHP, Paris, France
5 Hôpital Saint Antoine, APHP, Sorbonne Université, Paris, France
6 CHU Bordeaux, Bordeaux, France
7 IUCT Oncopole, Toulouse, France
8 CHU Toulouse, Université Toulouse III Paul Sabatier, Toulouse, France
9 Hôpital Henri Mondor, APHP, Université Paris-Est Créteil,, Créteil, France
10 Groupe Hospitalier Sud Ile de France, Melun, France
11 CHU Dijon, Université de Bourgogne, Dijon, France
12 CH Arras, Arras, France
13 CHU Saint-Etienne, Université de Lyon, Saint-Etienne, France
14 CHU Lille, Reference Center for Hypereosinophilic Syndromes (CEREO), Lille, France
15 CH Valenciennes, Valenciennes, France
16 CH Dax, Dax, France
17 CHU Grenoble, Université Grenoble Alpes, Grenoble, France
18 CH Saint-Quentin, Saint-Quentin, France
19 CH Annecy, Annecy, France
20 CHU Nantes, Université de Nantes, Nantes, France
21 CHU Poitiers, Faculté de Médecine et de Pharmacie de Poitiers, Poitiers, France
22 Foch Hospital, Reference center for Hypereosinophilic Syndromes (CEREO), Suresnes, France
23 Hôpital de la Timone, AP-HM, Aix-Marseille Université, Marseille, France
24 Ch Avignon, Avignon, France
25 CHU Lille, Reference Center for Hypereosinophilic Syndromes (CEREO), Lille, France
26 CHU Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France
27 CHU Lille, Lille, France
28 CHU Lille, Lille, France
29 CHU Lille, Lille, France
30 Foch Hospital, Reference center for Hypereosinophilic Syndromes (CEREO), Suresnes, France
31 Foch Hospital, Reference center for Hypereosinophilic Syndromes (CEREO), Suresnes, France
32 Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Bruxelles, Belgium
33 Hôpital Ambroise Paré, APHP, Reference center for Hypereosinophilic Syndromes (CEREO), Boulogne-Billancourt, France
ABSTRACT
Introduction. Hypereosinophilic syndromes (HES) are classified according to the mechanisms driving blood hypereosinophilia (HE) into neoplastic (N-HES), lymphocytic (L-HES), and idiopathic (I-HES) when no underlying cause is identified. Although these variants may present with similar clinical features at diagnosis, whether the risk of developing new organ involvement differs according to HES subtype remains unknown. In I-HES, 3 outcome profiles have been identified: a single-flare course with spontaneous remission or sustained remission after oral glucocorticoid (OGC) withdrawal (A), a relapsing-remitting course (B), and persistent disease requiring continuous OGC therapy to prevent relapse (C). Clinical phenotypes and treatment requirements across these three profiles have not been comprehensively described.
Methods. COHESion is an ongoing prospective, multicenter European cohort including adults and children with eosinophilic disorders (NCT04018118, Lefèvre et al., Allergy, 2025). We compared organ involvement at diagnosis (occurring before or within 6 months after diagnosis) in patients with I-HES, N-HES, and L-HES, and we assessed new organ involvement occurring during follow-up (beyond 6 months after diagnosis). Patients without HES-related manifestations were excluded. Baseline disease manifestations, cumulative OGC exposure, and biologic use were assessed according to I-HES outcome profiles. Continuous variables are expressed as medians [interquartile range] and were compared using the Kruskal-Wallis test. Categorical variables were compared using the chi-square test, followed by one-by-one post hoc comparisons after a significant global test.
Results. Among 1,052 enrolled patients, data were complete for 786, including 380 with I-HES, 32 with N-HES and 46 with L-HES. At diagnosis, gastrointestinal involvement was more frequent in I-HES (% in I/N/L-HES: 31/9/9%, p<0.001), and cutaneous-mucosal manifestations in L-HES (% in I/N/L-HES: 33/41/80%, p<0.001). After a median follow-up of 43 [15.5;84], 36 [21;68], and 67 [47;120] months, new organ involvements occurred in 11%, 16%, and 13% of patients with I-, N-, and L-HES, respectively. Only 12 new cardiac events were recorded (8 in I-HES, 1 in N-HES, and 3 in L-HES).
Among 380 patients with I-HES, 42 had insufficient follow-up for profile assignment. Of the remaining 338, disease profiles were distributed as follows: 37 (11%) A, 95 (28%) B, and 206 (61%) C.
Baseline manifestations preferentially associated with specific outcome profiles were gastrointestinal involvement (more frequent in Profile B; % in A/B/C: 30/56/26%, p<0.001), cutaneous-mucosal involvement (less frequent in Profile B; % in A/B/C: 49/22/41%, p<0.001), and venous or arterial thromboses (more frequent in Profile A; % in A/B/C: 24/2/6%, p<0.001).
Short courses of OGC (≤3 months) were administered as sole management in 8%, 21%, and 11% of patients with Profiles A, B, and C, respectively, while long-term OGC therapy was required in 46%, 54%, and 81%. The remaining patients were managed conservatively with observation alone or topical corticosteroids.
The median follow-up in Profile A (3.1 [1.8;5.7] months) was shorter than in Profiles B (5.8 [2.8;8.8], p=0.0055) and C (6.3 [3.3;9.6], p<0.001). Median cumulative OGC exposure was higher in Profile C (5.25 [1.5;12] grams) than in Profile A (0.2 [0;5.8], p<0.001) and Profile B (2.2 [0;6], p<0.001), while annualized OGC exposure was also highest in Profile C (1 [0.3;2.3] gram/year), compared with Profile A (0.08 [0;2], p=0.02) and Profile B (0.3 [0;1.45], p<0.001). Consistently, anti-IL-5/anti-IL-5R therapies were used as OGC-sparing treatment in 23% and 59% in Profile B and C patients, respectively, but in none of the patients with Profile A.
Conclusion. Organ involvement at diagnosis differed only modestly across HES variants. Moreover, few patients developed new organ involvement during follow-up and cardiac complications were uncommon compared with previous large case series (Ogbogu et al., JACI 2009), which may reflect earlier diagnosis and improved management. In I-HES, baseline clinical features have limited prognostic value for predicting the disease course. Persistent disease is characterized by substantially greater GC exposure and frequent use of anti-IL-5/anti-IL-5R therapies, underscoring the importance of identifying these clinical outcome profiles as early as possible to enable timely implementation of appropriate treatment.
DISCLOSURES
Guillaume Lefèvre, MD, PhD: GSK - Honoraria; AstraZeneca - Honoraria; GSK - Research Funding; AstraZeneca - Research Funding; AstraZeneca - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony)